The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- On December 13, 2024, the Board of Directors of AGF Management Limited declared a ...

BridgeBio Pharma (BBIO) announced the Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on ...

BridgeBio Pharma (BBIO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization in the European Union for acoramidis for ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations ...

A ketone body, a molecule derived from the metabolism of acids to obtain energy when glucose is not available, could become ...

BridgeBio Pharma, Inc. (NASDAQ: BBIO) recently announced that the U.S. Food and Drug Administration (FDA) has approved attruby™ (acoramidis), a near-complete stabilizer of transthyretin (TTR), for the ...

This week, the FDA issued recommendations for streamlining the clearance process for AI-powered medical devices. The memo announcing this change recognizes that the utilization of AI in devices “is an ...